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CObjectives: To develop a stochastic population model of disease pro-
gression in chronic obstructive pulmonary disease (COPD) that in-
cludes the effects of COPD exacerbations on health-related quality of
life, costs, disease progression, andmortality and can be used to assess
the effects of a wide range of interventions. Methods: The model is a
multistate Markov model with time varying transition rates speci-
fied by age, sex, smoking status, COPD disease severity, and/or ex-
acerbation type. Themodel simulates annual changes in COPD prev-
alence due to COPD incidence, exacerbations, disease progression
(annual decline in the forced expiratory volume in 1 second as per-
centage of the predicted value), and mortality. The main outcome
variables are quality-adjusted life years, total exacerbations, and
COPD-related health care costs. Exacerbation-related input param-
eters were based on quantitative meta-analysis. All important
model parameters are entered into the model as probability distri-
butions. To illustrate the potential use of the model, costs and ef-
fects were calculated for 3-year implementation of three different O
y, Ins
al So
doi:10.1016/j.jval.2011.06.008OPD interventions, one pharmacologic, one on smoking cessation,
nd one on pulmonary rehabilitation using a time horizon of 10
ears for reporting outcomes. Results: Comparedwithminimal treat-
ent the cost/quality-adjusted life year was €8,300 for the pharmaco-
ogic intervention, €10,800 for the smoking cessation therapy, €8,700 for
he combination of the pharmacologic intervention and the smoking
essation therapy, and €17,200 for the pulmonary rehabilitation pro-
ram. The probability of the interventions to be cost-effective at a ceil-
ng ratio of €20,000 varied from 58% to 100%. Conclusions: The COPD
odel provides policy makers with information about the long-term
osts and effects of interventions over the entire chain of care, from
rimary prevention to care for very severe COPD and includes uncer-
ainty around the outcomes.
eywords: chronic obstructive pulmonary disease, exacerbations,
odel, progression, probabilistic.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by
progressive airflow limitation that is not fully reversible [1]. The
main risk factor is smoking and themost important symptoms are
chronic dyspnea, cough, and sputum production. The progression
of COPD is often accompanied by periods of increasing symptoms,
known as exacerbations, which were found to be associated with
increased mortality, impaired health-related quality of life, and
increased health care use [2,3].
The worldwide burden of COPD in terms of morbidity, mortal-
ity, and health care costs is substantial and is expected to increase
in the future, mainly due to aging and continuing tobacco use. A
US study [4] showed that among six major causes of death COPD
was the only condition for which mortality rates have increased
between 1970 and 2002 and these rates were expected to increase
continuously. Furthermore, COPD was projected to be one of the
leading causes of mortality and disability in 2020 worldwide [5].
* Address correspondence to:M. Hoogendoorn, Erasmus Universit
Rotterdam, The Netherlands.
E-mail: hoogendoorn@bmg.eur.nl.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.Against this background health policy makers need information
about the options for prevention and treatment of COPD in terms
of both effects and costs.
In a slowly progressing disease such as COPD,modelling can be
a useful tool to estimate the medium and long-term effects and
costs of interventions. Next to that, modelling is also useful to
combine existing knowledge from various sources in a consistent
way. In the past decade nine different COPD progression models
have been published [6–14]. All these models are Markov models
and comparable with respect to COPD severity based on the forced
expiratory volume in 1 second (FEV1) as percentage of the pre-
dicted value, progression based on lung function decline, and in-
clusion of exacerbations. Structural differences between themod-
els exist regarding the number of COPD severity stages, duration of
the Markov cycles, inclusion of the risk factors age and smoking,
distinction in severity of exacerbations, and inclusion of COPD
incidence. Furthermore, the models substantially differ in utility
values assigned to COPD stages and utility decrements assigned to
exacerbations [15]. Finally, not all themodels take into account the
titute for Medical Technology Assessment, P.O. Box 1738, 3000 DR
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
1040 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 3 9 – 1 0 4 7uncertainty around the input parameters, which is currently re-
garded as essential in cost-effectiveness analyses [16,17].
Because most of the COPD models were built to evaluate a
specific intervention in a specific population, mostly to support
reimbursement negotiations of newmedications, theymay be less
suitable to evaluate other types of interventions. This is, for exam-
ple, reflected in the fact that model parameters such as transition
probabilities and exacerbation rates were often obtained from one
or a few clinical trials investigating the medication of interest. In
suchmodels, disease progression is often similar regardless of sex,
age, and smoking status, whichmake thesemodels less suitable to
simulate the effect of, for example smoking cessation interven-
tions, on disease progression.
The aim of this study was to develop a dynamic population
model of disease progression in COPD from diagnosis of the dis-
ease until death. In contrast to our earlier model [9,18], the new
model includes the effects of COPD exacerbations, allows for prob-
abilistic sensitivity analysis and can be used to evaluate a wide
range of COPD interventions, from prevention to treatment. This
article primarily describes the structure of the new model and the
estimation of the new exacerbation-related input parameters. The
potential use of the newmodel is illustrated by calculating the cost-
effectiveness of three different COPD interventions compared with
minimal treatment.
Methods
Description of the model structure
The COPD model is not a straightforward simple discrete stage
Markov model, but it may be classified as a Markov-type model, be-
cause theMarkovproperty is a prominent aspect of the entiremodel.
The model has six main health states, no COPD, four COPD severity
Fig. 1 – Description of the Dutch chronic obstrustages based on the Global Initiative for chronic Obstructive LungDisease (GOLD) classification [1], and death, which are further strat-
ified by sex, age, and smoking status. COPD severity stages are fur-
ther characterized by their distribution of lung function; that is, FEV1
as percentage of the predicted value. The cycle length of themodel is
one year and the time horizon of the analyses can vary between 1
year and lifetime. Figure 1 illustrates the structure of themodel. The
model followsbirth cohorts over time. Eachyear anewbirth cohort is
added, while the existing cohorts age with 1 year. Within each birth
cohortpeople canmovebetweensmokingclasses, bediagnosedwith
COPD,move to another COPD severity stage, or die, all with a certain
annual probability. These probabilities depend on the relevant cova-
riables age, sex, lung function, and smoking status.
The model starts with the Dutch general population and the
COPD patient population in 2007 specified by sex, 1-year age
classes, smoking status (smokers/former smokers/never smok-
ers), and COPD severity. COPD patients are divided into four sever-
ity stages according to their lung function, expressed as the FEV1%
predicted. Themodel then simulates the annual changes in the gen-
eral population aswell as the COPDpopulation. The dynamics in the
Dutch general population are taken into account using prognoses of
birth andmortality aswell as estimates of the start, stop, and restart
rates of smoking, whereas changes in the COPD population are the
result of incidence, changes in smoking status, disease progression,
and mortality (see Fig. 1). In each severity stage COPD patients have
an annual probability to experience exacerbations. Exacerbations in
themodelwere defined based on an increase in health care use; that
is, an event-based definition. A distinction wasmade betweenmod-
erate (nonsevere) and severe exacerbations. A moderate exacerba-
tion was defined as an exacerbation leading to a prescription of sys-
temic corticosteroids and/or antibiotics and a severe exacerbation
was defined as a hospitalization for COPD. Total exacerbations were
calculated as the sum of both moderate and severe exacerbations.
Exacerbations were modelled to affect disease progression, mortal-
pulmonary disease (COPD) population model.ctiveity, quality of life, and costs.
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able to COPD andmortality due to other causes. COPD-attributable
mortality was defined as the independent mortality risk related to
having COPD; that is, which is adjusted for the mortality risk from
smoking. This adjusted COPD-related mortality risk is smaller
than the unadjusted risk, because having COPD is largely corre-
lated with smoking, and smoking increases the mortality risk
through many more chronic diseases other than COPD. COPD-
attributable mortality was modelled as being dependent on sex,
age, and FEV1% predicted (Relative risk [RR] 1.2; 95% CI 1.16–1.23)
er 10-unit decline [19] andwas further divided into exacerbation-
elatedmortality and remaining COPDattributablemortality.Mor-
ality from other causes was modelled to depend on sex, age, and
moking status and included the mortality from other smoking-
elated diseases. To avoid double counting, COPD-attributable
ortality was not modelled to depend on smoking status because
he influence of smoking onmortality due to COPD is already cap-
ured by the increased incidence and prevalence of COPD among
mokers and former smokers. This means that a smoking and
ormer smoking patientwith the same sex, age, and COPD severity
tage were assumed to have the same risk to die of COPD. Patients
ho smoke, however, have a higher COPD-attributable mortality
isk over time, because they progress faster to more severe COPD
tages, which are associated with a higher mortality risk. More
etails about the model structure can be found elsewhere [20].
Outcomes
The main outcome variables of the model are the total annual
number of life years, quality-adjusted life years (QALYs),moderate
and severe COPD exacerbations, total mortality, and total COPD-
related health care costs. The annual number of life years is cal-
culated as the annual number of patients alive. The annual num-
ber of QALYs is calculated as the annual number of life years
weighted by their quality of life during these years using EQ-5D
utility weights specified by COPD severity [6]. For each exacerba-
tion a decrement in utility weights is applied [21,22]. Total mortal-
ity is defined as the annual number of deaths with a COPD-related
cause plus the annual number of deaths due to other causes. The
annual COPD-related health care costs are calculated bymultiply-
ing the number of patients alive with the COPD-related mainte-
nance costs per patient specified by sex, age and COPD severity
and adding the additional costs of exacerbations.
Demographic, smoking, and COPD nonexacerbation-related
input parameters
Data on demography and prognoses of birth and mortality for the
year 2007 were obtained from Statistic Netherlands [23], whereas
prevalence of smoking and changes in smoking status in the pop-
ulation; that is, start, stop, and restart rates, were based on data
from STIVORO [24–26], all specified by sex and 1-year age classes.
Data on COPD prevalence, incidence, and mortality for 2007, in-
cluding uncertainty, were obtained from general practice (GP) regis-
trations [27,28].Asalmost allDutchcitizensare registeredat aGP, the
model is representative of the Dutch population of diagnosed COPD
patients.
Prevalence, incidence, and mortality by sex and age were fur-
ther specified by smoking status using the relative risks of smok-
ers and former smokers to die of COPD [29,30]. The COPD preva-
lence within each subclass by sex, age, and smoking status was
then further divided across the four GOLD stages of COPD severity
[1] using the estimated normal distribution of the FEV1% predicted
of COPD patients in two Dutch GP practices (68.3 19.9), which led
to the following distribution: 27% mild (FEV1 predicted  80%), 55%
moderate (FEV1 predicted  80% and 50%), 15% severe (FEV1 pre-
dicted50%and30%), and3%very severeCOPD (FEV predicted1
30%) [31]. The severity distribution of the incidence was estimated fby the model and defined as the distribution that—given disease
progression and mortality—would not change the FEV1% pre-
dicted among the prevalent cases in the first year of the model.
Based on this estimated normal distribution (76.4  15.6), the se-
verity distribution of the incidence was estimated to be 40% in
mild, 55% inmoderate, 4% in severe, and 0.1% in very severe COPD.
Disease progression was modelled as the annual decline in
FEV1% predicted based on a reanalysis of the original 5-year Lung
ealth Study data [32,33]. A random effect model was used to
stimate the annual decline in FEV1% predicted depending on sex,
age, smoking status, and baseline FEV1% predicted [9]. The values
oundwere not translated into transition rates as is common in all
ther models, but modelled directly as the change in the distribu-
ion of FEV1% predicted for the total group of patients within a
certain COPD state. A new division across the severity stages was
made at each annual step after all changes had been simulated
using the cut-off points for the different GOLD severity stages
(FEV1 predicted of 80%, 50%, and 30%).
The main input parameters for mortality were all-cause mor-
ality obtained from Statistic Netherlands [34] and COPD excess
ortality [28]. The COPD-attributable mortality was calculated as
he COPD excess mortality adjusted for smoking status. Mortality
ue to other causes was estimated as the total mortality among
OPD patients minus the COPD-attributable mortality.
The total direct medical costs for COPD in the Netherlands
pecified by sex and age were obtained from a previous cost of
llness study for the year 2000 [35]. These costswere updated to the
ear 2007 using consumer price indices [36]. We did not update
hese data using newer cost of illness studies, becausewe aimed to
epresent minimal treatment and the resource use estimates of
000 best reflected this type of treatment. The COPD-relatedmain-
enance costs were calculated as the total direct medical cost per
ex and age class minus the exacerbation-related costs per sex
nd age class. The maintenance costs within each sex and age
lass were further divided over the severity stages using ratios for
he total COPD costs of a patient with moderate (1.24), severe
1.39), or very severe COPD (2.06) compared to the costs of a patient
ith mild COPD (1.0) as observed in Dutch studies [10,37]. The
ain input parameters of the model are shown in Table 1 and
urther specified elsewhere [20].
COPD exacerbation-related input parameters
The new exacerbation-related parameters were based on quanti-
tative meta-analyses. These parameter estimates can be regarded
as results of this study, but are presented in the Methods section
because it concerns input parameters.
Exacerbation frequency by COPD severity. The frequency of total
and severe exacerbations by GOLD severity stage was based on a
systematic literature review and meta-analysis of randomized
controlled trials and cohort studies reporting altogether 19 differ-
ent estimates of the total exacerbation frequency and 14 different
estimates of the severe exacerbation frequency in patients receiv-
ing usual care or placebo. The association between the mean
FEV1% predicted of the study populations in the selected studies
nd the annual exacerbation frequencies was estimated. The es-
imated equationswere used to calculate the total number and the
umber of severe exacerbations per GOLD stage. Based on the
ean FEV1% predicted per GOLD severity stage in the first year,
he average number of total exacerbations in the first year was
stimated to be 0.82 (95% CI 0.46–1.49) for mild, 1.17 (95% CI 0.93–
.50) for moderate, 1.61 (95% CI 1.51–1.74) for severe, and 2.10 (95%
I 1.51–2.94) for very severe COPD. The severe exacerbations rates
ere 0.11 (95% CI 0.02–0.56), 0.16 (95% CI 0.07–0.33), 0.22 (95% CI
.20–0.23), and 0.28 (95%CI 0.14–0.63), respectively. The estimated
egression equations were built into the model to capture the ef-
ect of changes inmean FEV1% predicted over timewithin a sever-
r
d
l
69 y,
1042 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 3 9 – 1 0 4 7ity stage on the exacerbation frequency. All details about the esti-
mation of the exacerbation frequencies specified by GOLD severity
stage have been reported elsewhere [38].
Case-fatality of exacerbations. Mortality was assumed to be in-
creased after a severe exacerbation only, not after a moderate
exacerbation. The case-fatalitywas calculated as the probability of
mortality after a severe exacerbation corrected for the mortality
probability during a stable disease period. This was based on six
studies reporting at least 1.5-year survival after a severe exacer-
bation that allowed us to separate the survival curve after hospital
admission into a critical and a stable period. The case-fatality of a
Table 1 – Main input parameters for the model for the refe
pulmonary disease (COPD) severity stage.
Prevalence (2007) as % of general population  45 y:
- Men
Never smokers
Smokers
Former smokers
- Women
Never smokers
Smokers
Former smokers
Incidence (2007) as % of general population  45 y:
- Men
Never smokers
Smokers
Former smokers
- Women
Never smokers
Smokers
Former smokers
Annual decline in FEV1% predicted*:
- Men
Never smokers/former smokers
Smokers
- Women
Never smokers/former smokers
Smokers
COPD attributable mortality (2007)*:
- Men
- Women
Mortality due to other causes (2007)*:
- Never smokers
- Smokers
- Former smokers
Utilities: 0.89
COPD costs for maintenance per patient (€, 2007)*:
- Men €1
- Women €3
Smoking prevalence in the general population  45 y:
- Never smokers
- Smokers
- Former smokers
Smoking transition rates in the general population  45 y:
- Start
- Stop
- Restart
FEV1, forced expiratory volume in 1 second.
* Data have been specified by age. The Table presents values for agesevere exacerbation was estimated to be 15.6% (95% CI 10.9%– i20.3%) on average. This case-fatality was applied to the mean age
of the COPD population in the articles selected from the literature;
that is, 69 years. The relation between age and mortality was also
estimated (RR 1.041; 95% CI 1.037–1.045) per year increase in age)
and used in the model to make the case-fatality rate age-depen-
dent. Further details about the estimation of the case-fatality of a
severe COPD exacerbation have been reported elsewhere [39].
Exacerbations and lung function decline. Five studies were found
eporting the relation between exacerbations and lung function
ecline [40,41–44]. Only one study directly reported the decline in
ung function per lower respiratory illness [42]. For the other stud-
scenario specified by sex and/or chronic obstructive
COPD severity stage
Moderate Severe Very severe
0.06 0.02 0.003
0.85 0.24 0.04
2.05 0.57 0.10
0.25 0.07 0.01
0.74 0.21 0.04
1.34 0.37 0.06
5 0.007 0.0005 0.00001
0.11 0.008 0.0002
0.24 0.02 0.0004
0.03 0.002 0.00005
0.10 0.007 0.0002
0.15 0.01 0.0003
1.20 1.56 1.85
1.54 1.89 2.18
1.17 1.52 1.81
1.51 1.86 2.15
4.5% 6.9% 9.6%
3.0% 4.6% 6.3%
Men: 1.0%, women: 0.6%
Men: 2.4%, women: 1.4%
Men: 1.2%, women: 0.7%
1117) 0.7551 (0.2747) 0.7481 (0.2991) 0.5493 (0.3129)
) €169 (25) €187 (28) €277 (42)
) €405 (61) €452 (68) €671 (101)
Men: 18%, women: 39%
Men: 27%, women: 22%
Men: 54%, women: 39%
Men: 0.5%, women: 0.1%
Men: 6.5%, women: 6.5%
Men: 1.3%, women: 1.4%
the mean age of the COPD population in the model.rence
Mild
0.03
0.41
0.98
0.12
0.36
0.64
0.00
0.08
0.17
0.02
0.07
0.11
0.83
1.16
0.79
1.13
2.8%
1.9%
71 (0.
35 (20
26 (49es the decline in lung function due to an exacerbation was esti-
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1043V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 3 9 – 1 0 4 7mated by dividing the difference in lung function decline between
patients with infrequent and frequent exacerbations as defined in
the specific study by the difference in exacerbations between the
two groups. The average decline in lung function per exacerbation
was estimated to be 0.19% predicted (95% CI 0.092–0.29).
Exacerbations and quality of life. Only two studies reported
bout exacerbations and quality of life using the EuroQol, one for
evere and one for moderate exacerbations. O’Reilley et al. [22]
resented utility values at admission and discharge for a COPD
ospitalization based on the UK value set. Based on these values,
0.077 and 0.576 respectively, the mean length of hospitalization
f 11 days, the assumption that the utility value would have re-
urned to normal; that is, 0.689, after 4.5 months [39] and the as-
sumption of a linear increase between admission and discharge
and discharge and baseline, the annual utility loss due to a severe
exacerbation was estimated to be 4.82% (95% CI 3.11–6.53) from
the baseline utility value. The annual utility loss due to amoderate
exacerbation, 1.66% (95% CI 1.23–2.09) of the baseline value, was
derived from a study by Goossens et al. [21], who measured utility
scores during a moderate exacerbation at four different time
points over a period of 6 weeks.
Costs of exacerbations. The costs per moderate and severe exac-
rbation were based on a study conducted by Oostenbrink et al.
45]. Because of the difference in exacerbation definition with our
odel we slightly modified the cost estimate of a moderate exac-
rbation by deleting the inpatient hospital costs for a nonsevere
xacerbation. The final cost estimates were updated to the year
007 resulting in a cost estimate of €94 (95% CI 80–108) for a mod-
rate and €4100 (95% CI 2348–5852) for a severe exacerbation.
Intervention scenarios
All reference values of the input parameterswere as far as possible
estimated from data sources in which patients received minimal
treatment. Data were obtained from cohorts receiving usual care
in older studies or from the placebo arm of a trial or the arm
receiving a nonintensive intervention. Therefore a model simula-
tion using the reference values of the input parameters reflects the
situation in which patients receive minimal treatment (“minimal
treatment scenario”). To illustrate the possibilities of themodelwe
calculated the cost-effectiveness for four scenarios (three differ-
ent interventions) compared with minimal treatment. For ease of
interpretation, all cost-effectiveness analyses were performed for
a fixed cohort of patients; that is, setting COPD incidence to zero.
The first scenario evaluatedwas the implementation of a phar-
macologic combination therapy of a long-acting 2 agonistwith an
Table 2 – Input data for the intervention scenarios (95% con
Combination of a long-acti
bronchodilator and an
inhaled corticosteroid
Target population Moderate and severe COPD
Percentage of patients receiving
the intervention
50%
Annual smoking cessation rate 
Annual decline in lung function RR0.60 (0.45–0.76) [44,46]
Total exacerbation frequency RR0.75 (0.69–0.81) [44,46]
All-cause mortality at three year HR0.825 (0.681–1.002) [44,46]
Annual change in utility 
Annual intervention costs €773
COPD, chronic obstructive pulmonary disease; HR, hazard ratio; RR, rinhaled corticosteroid (ICS/LABA). Effects of this therapy weremodelled as a reduction in lung function decline, exacerbation
frequency, and all-cause mortality. The size of these benefits was
obtained from the TORCH trial [44,46] and given in Table 2. Directly
applying the RRs to all three parameters independently would
overestimate the effect of the intervention, because lung function,
exacerbation rate, and mortality are related to each other in the
model. Therefore the effect of the intervention was modelled in
three steps. In Step one the effect on lung function decline was
applied. If the effect of the decrease in decline on exacerbation
frequencywas smaller than the effect seen in the trial, the effect of
the intervention on exacerbation frequency was adjusted till the
magnitude of the effect observed in the trial (Step two). After that,
the effect of the first two steps on all-cause mortality was deter-
mined. Finally, in Step three the effect on mortality was adjusted
till the effect seen in the trial. The second scenario assumed in-
creased implementation of intensive counselling plus pharmaco-
therapy for smoking COPD patients, leading to increased smoking
cessation rates (Table 2) [18]. In the model, increased smoking ces-
sation leads to a one-time increase in FEV1% predicted, a lower an-
nual decline in lung function (based on the Lung Health Study [33]),
and reduced mortality due to COPD and other smoking-related dis-
eases. In Scenario three implementation of the combination of the
first two interventions, ICS/LABA for all patients with moderate and
severe COPDand intensive counselling plus pharmacotherapy for all
smoking COPD patients was evaluated. Because the TORCH trial did
not found a significant interaction between treatments and smoking
status [46], we assumed no interaction effect between the pharma-
cologic intervention and the smoking cessation therapy; that is, ef-
fects were assumed additive. In Scenario four, implementation of an
interdisciplinary community-based pulmonary rehabilitation pro-
gram was simulated, using a trial-based estimate of its costs and
effect on quality of life (Table 2) [47].
Table 2 also shows the type and percentage of patients receiv-
ing the intervention and the intervention costs. All interventions
were assumed to be implemented for 3 years and evaluated using
a time horizon of 10 years. A 3-year implementation period im-
plied that the benefits and costs of the interventions were applied
for 3 years and that after 3 years all input parameters returned to
the reference values, representing minimal treatment. The four
intervention scenarios were compared with the minimal treat-
ment scenario to estimate the number of QALYs gained, the
number of exacerbations avoided, the incremental intervention
costs and the savings in COPD-related health care costs. Health
outcomes were discounted by 1.5%; costs by 4% [48]. The costs
per QALY gained and exacerbation avoided for each interven-
tion scenario were calculated as the total incremental interven-
nce interval).
Intensive counselling plus
pharmacotherapy for
smoking cessation
Pulmonary rehabilitation
Mild, moderate, severe and
very severe COPD
Moderate and severe COPD
50% 15%
10.9% (6.0–15.0%) [18] 
 
 
 
 0.043 (-0.005–0.090) [47]
€305 €745
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avoided, respectively.
Sensitivity analyses
To estimate the effects of the uncertainty around the different
input parameters on the outcomes a probabilistic sensitivity anal-
ysis was performed. The parameters included in the sensitivity
analysis with their mean and standard error and applied distribu-
tion have been described in Appendix A (found in Supplemental
Materials at: doi:10.1016/j.jval.2011.06.008). Monte Carlo simula-
ion was conducted by drawing random values from all parame-
ers distributions, after which the model was run for each set of
arameters and results of each run were collected. Monotonicity
as enforced for the utility weights and COPD-related mainte-
ance costs by COPD severity. For utility values for example this
eans that in each simulation the randomly drawn value formild
OPD needed to be higher than the value drawn for moderate
OPD and the value for moderate needed to be higher than for
evere COPD. The current analyses were based on 1000 simula-
ions, providing the 95% uncertainty interval around the effects
nd costs. The uncertainty was displayed in cost-effectiveness
lanes and acceptability curves [49–51].
In addition to the probabilistic sensitivity analyses we per-
formed several one-way sensitivity analyses for all intervention
scenarios for a number of key model parameters and for model
parameters for which a probabilistic approach was not appropri-
ate, such as discount rate. In the first sensitivity analysis we in-
vestigated the effect of a 50% higher or lower annual decline in
FEV1% predicted. In Sensitivity Analysis two to six we investigated
he effect of using either the 95% lower limit or the 95% upper limit
f the five exacerbation-related parameters: the baseline exacer-
ation frequencies per severity stage, the case-fatality, the decline
n lung function, the utility loss, and the costs. In Sensitivity Ana-
ysis seven the 95% CI limits for the utility values by COPD severity
tage were applied. In Sensitivity Analysis eight we investigated
he effect of using a lower smoking cessation rate for COPD pa-
ients in the reference scenario, 1.4% [52]. The effect of a 10% re-
uction or increase in intervention costs was assessed in Sensitiv-
ty Analysis nine. Using discount rates of 0% or 4% for both costs
nd effects was investigated in Sensitivity Analysis 10 and in Sen-
itivity Analysis 11 we performed analyses using a time horizon of
and 20 years.
Results
The COPD population in 2007, the starting year of the simulation,
consisted of 321,000 patients older than 45 years of age. Forty-six
percent of patientswere female andmean agewas 69 years. Thirty
percent of patients were estimated to be current smokers,
whereas 64%were former smokers. Themajority of patients (82%)
had mild or moderate COPD. About two-third of the total COPD-
related health care costs of €352.8 million in 2007 for a minimal
treatment scenario were exacerbation-related.
The results for the four interventions scenarios are shown in
Table 3. The mean cost per QALY gained compared with minimal
treatment varied between €8,300 and €17,200. The costs per exacer-
ation avoided varied between €2,600 for the ICS/LABA intervention
nd around €400,000 for the smoking cessation scenario. The latter
atio is high because smoking cessation extends life expectancy and
atients are therefore longer at risk to get an exacerbation. Pulmo-
ary rehabilitation was not assumed to affect exacerbation fre-
uency, so the costs per exacerbation avoided were not calculated.
The results of the probabilistic sensitivity analysis are shown
n Figures 2 and 3. For Scenario one to three; that is, implementa-
ion of ICS/LABA, intensive counselling plus pharmacotherapy for
moking cessation or a combination of these two interventions,T p a 1 2 3 4 IC
1045V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 3 9 – 1 0 4 7100% of all model replications fell in the upper right quadrant
indicating more QALYs and higher costs compared with minimal
treatment. For Scenario four on pulmonary rehabilitation this per-
centage was 96%. The probability to be cost-effective at a willing-
ness-to-pay value of €20,000 per QALY gained was 99.9% for ICS/
LABA, 97.3% for pharmacotherapy for smoking cessation, 99.8%
for the combination of ICS/LABA and smoking cessation, and 58%
for pulmonary rehabilitation (Fig. 3).
The one-way sensitivity analyses showed that for the first
three scenarios the cost per QALY gainedwasmost sensitive to the
timehorizon chosen and the baseline exacerbation frequencies (in
Appendix B in Supplemental Materials at: doi:10.1016/j.jval.
2011.06.008). For the scenario on pulmonary rehabilitation a 10%
reduction or increase in intervention costs or changes in utility
values for the COPD severity stages had the greatest influence on
the cost per QALY.
Discussion
This study aimed to develop a dynamic, stochastic population
Fig. 2 – Cost-effectiveness planes for 3-year implementation
bronchodilator (LABA); 2) pharmacotherapy plus intensive c
and pharmacotherapy plus intensive counselling for smokin
compared with minimal treatment, time horizon 10 years, dmodel of disease progression in COPD including the effects of ex-acerbations. We described the structure of the model and showed
the potential of the model by evaluating three different COPD in-
terventions. One of the strengths of the model is that many of the
input parameters of the model were obtained from systematic
reviews, using quantitative analysis to combine data from multi-
ple sources. The annual frequency of moderate and severe exac-
erbations, the case-fatality of a severe exacerbation, and the effect
of exacerbations on lung function decline and quality of life were
all estimated by quantitative meta-analysis, which improves the
quality of the parameter estimates.
The model is also up to date because it can generate uncer-
tainty around the estimated results using probabilistic sensitivity
analyses. The uncertainty around estimates of all important pa-
rameters has been included. We did not take into account struc-
turalmodel uncertainty [16]. Thismeans for example that a reduc-
tion in the number of severe exacerbations always results in a
reduction of the case-fatality and a gain in utility. These assump-
tions, however, are clinically very plausible.
A limitation of themodel is that the severity and progression of
COPD are only based on lung function; that is, FEV % predicted. It
) inhaled corticosteroid (ICS) with long-acting
elling for smoking cessation; 3) combination of ICS/LABA
ssation; and 4) pulmonary rehabilitation program. All
unt rates: 1.5% effects; 4% costs.of 1
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ness and fatigue, the level of exercise impairment, and the exis-
tence of comorbidities [1]. Compositemeasures, such as the BODE,
DOSE or ADO, which include variables such as body mass idex,
airflow obstruction, dyspnea, exercise capacity, age, smoking sta-
tus, or exacerbation frequency are better predictors of disease se-
verity than lung function alone [53–55]. The progression of COPD is
also not only influenced by the decline in lung function [56]. It is
very difficult if not impossible to obtain detailed data for so many
different variables from national registries and hospital and GP
databases. For reasons of availability and simplicity the severity
and progression of COPD in the model is therefore only based on
lung function as is done in all other available COPD models.
Up to now, besides our model, eight other COPD models have
been published [6–8,10–14]. Seven of themodels take into account
uncertainty around input parameters in a more or less elaborate
way [6-10,12,14] and three are population-based; that is, represen-
tative for a total nationwide COPD population [9,11,13]. The ma-
jority of themodels have been developedwith financial support of
pharmaceutical companies and sixmodelswere built to evaluate a
specific pharmacologic treatment. Five models were used to inves-
tigate the influence of implementation of inhaled corticosteroids
with or without long-acting -agonist bronchodilator for a (sub-)
roup of COPD patients [7,8,11,12,14], whereas one model was used
o evaluate implementation of the long-acting anticholinergic
ronchodilator tiotropium [10]. Because these models have been
uilt to evaluate a specific intervention, input parameters not rel-
vant for the intervention under evaluation, such as disease pro-
ression are often modelled as one single value of FEV1 decline
hat is not depending on sex, age, or smoking. This type of simpli-
cations in input parameters and assumptions can make a model
ess suitable to evaluate other types of interventions.
The potential of our model was demonstrated by showing the
esults for four intervention scenarios. By choosing three com-
letely different interventions we tried to emphasize that the
odel can be used to evaluate a wide range of interventions. The
odel can be used to evaluate interventions that have an effect on
OPD incidence rates, smoking rates, lung function decline, qual-
ty of life, mortality, and/or frequency and severity of exacerba-
ions. To make the results of the scenarios as realistic as possible,
e applied the intervention to a realistic target population in
erms of disease severity and percentage of patients receiving the
Fig. 3 – Acceptability curves for inhaled corticosteroid
with long-acting bronchodilator (ICS/LABA)=black solid,
pharmacotherapy for smoking cessation=grey solid,
combination of ICS/LABA, and pharmacotherapy for
smoking therapy=grey dashed, pulmonary
rehabilitation=black dashed.ntervention. To make the results of the scenarios more valid, ef-ectiveness should have been taken from a systemic review, and
ot from one trial as was done for two interventions. This will be
art of future research. To increase comparability between the
cenarios we applied the same implementation duration and time
orizon for all scenarios. The optimal time horizon was however
ifferent for each scenario. For pharmacotherapy a time horizon
f 10 years seemed plausible, but for the smoking cessation sce-
ario that was too short to capture all health gains because the
nnual gain in QALYs was maximal around 10 years. Extensive
ne-way sensitivity analyses showed that results of the scenarios
ere very sensitive for the time horizon used. It is therefore very
mportant to use a well-based estimate of the most realistic time
orizon for each intervention. For the scenarios on pharmacother-
py and smoking cessation baseline exacerbation frequencies also
nfluenced the results substantially.We are rather confident about
he exacerbation frequencies because these were obtained from a
ystematic review.
Although a large part of the input data of the model are based
n international data, the model as described in this article is
epresentative of the Dutch COPD population, because it is filled
ith Dutch data on epidemiology of COPD and costs. To transfer
he model to another country, setting-specific input data on prev-
lence, incidence, mortality, smoking prevalence, and costs
hould replace the Dutch data (if they are expected to differ). All of
hese input data are listed in separate files that are imported into
he model and are therefore easy to adapt.
Conclusions
This article described the structure of an up-to-date COPD pro-
gression model, with input parameters as much as possible based
on systematic reviews. The model can be used to provide policy
makers with information about the long-term costs and effects of
interventions across the entire chain from primary prevention to
care for very severe COPD. Furthermore it also gives insight into
the uncertainty around the outcomes. The model has been devel-
oped without any industry support and hence provides an inde-
pendent tool for evaluation.
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